Shares of DBV Technologies surged after it received positive regulatory updates in the U.S. and Europe for its Viaskin Peanut allergy patch. The stock was up 47% to $1.03 in post-market trading on ...
As many as 30% of people living with severe hemophilia A develop inhibitors such as TFPI, which can be produced by the body’s immune response to clotting factors in replacement therapy, often limiting ...
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT TrialSAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- , (Nasdaq: TVTX) ...
In addition, the FDA awarded an Orphan Products Development grant to support the evaluation of HyBryteTM for expanded treatment in patients with early-stage CTCL, including in the home use setting.